Regulatory News For Rare Disease Products-Hot Stocks: BLUE, ICPT, SRPT

Rare or orphan diseases are a favored business model and strategy favored by entrepreneurs, bankers and analysts because the cost effectiveness of the drug can be rationalized, even with very high pricing in excess of $100k per year per patient.